Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.65 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.65 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | XBP1 | P17861 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | RARB | P10826 | 1/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | DPP4 | P27487 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191327 | 1.00 | LMNA (0.72) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL13576349 | 0.97 | EPHA2 (0.68) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL140568 | 0.97 | EPHA2 (0.68) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL8186971 | 0.90 | LMNA (0.73) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL29389843 | 0.90 | LMNA (0.73) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL41134 | 0.90 | LMNA (0.73) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL9735079 | 0.88 | EPHA2 (0.74) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL140567 | 0.86 | EPHA2 (0.69) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL29493446 | 0.86 | EPHA2 (0.69) | LMNAKDM4EHSD17B10ALDH1A1HPGD | |
| Alatrofloxacin SCHEMBL7101443 | 0.86 | EPHA2 (0.69) | LMNAKDM4EHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-3678715-B1 | CALENDERED SURGICAL MESHES COMPRISING POLYHYDROXYALKANOATES | TEPHA INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-4442767-A2 | METHODS FOR 3D PRINTING OF POLY-4-HYDROXYBUTYRATE | Tepha, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| EP-3802062-B1 | METHODS FOR 3D PRINTING OF POLY-4-HYDROXYBUTYRATE | TEPHA INC (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| WO-2017192494-A1 | HEMOSTATIC DEVICES AND METHODS OF USE | TYRX, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-20170319754-A1 | HEMOSTATIC DEVICES AND METHODS OF USE | TYRX, INC. (US) | 2017-11-09 | — | — | US | claimed |
| EP-3230500-A1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | Tepha, Inc. (US) | 2017-10-18 | — | — | EP | claimed |
| EP-3197512-A1 | ORIENTED P4HB IMPLANTS CONTAINING ANTIMICROBIAL AGENTS | Tepha, Inc. (US) | 2017-08-02 | — | — | EP | claimed |
| US-20170081784-A1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA, INC. | 2017-03-23 | — | — | US | claimed |
| US-9555155-B2 | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof | TEPHA, INC. (US) | 2017-01-31 | — | — | US | claimed |
| US-20160166727-A1 | Methods of Orienting Multifilament Yarn and Monofilaments of Poly-4-Hydroxybutyrate and Copolymers Thereof | TEPHA, INC. | 2016-06-16 | — | — | US | claimed |
| WO-2016048950-A1 | ORIENTED P4HB IMPLANTS CONTAINING ANTIMICROBIAL AGENTS | TEPHA, INC. (US) | 2016-03-31 | — | — | WO | claimed |
| US-20160082160-A1 | ORIENTED P4HB IMPLANTS CONTAINING ANTIMICROBIAL AGENTS | TEPHA, INC. | 2016-03-24 | — | — | US | claimed |
| EP-1121933-A1 | Premixed alatrofloxacin injectable compositions | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | FLT4 978/4885SLC6A3 842/4885DRD1 2493/4885 |
| US-20170319754-A1 | HEMOSTATIC DEVICES AND METHODS OF USE | PLAT, HABP2, F2 | FLT4 2820/4885SLC6A3 4838/4885DRD1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.